Clear All
731 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Regorafenib Stivarga 40 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT,RET,TIE2,DDR2,TrkQ,RAF,BRAF,SAPK2, PTK, Abl Yes 2012 In Use
NA Relugolix Orgovyx 120mg Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist Yes 2020 In Use
NA Ribociclib Kisqali 200 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Ribociclib and letrozole Kisqali Femara Co-pack 200 mg/ 2.5 mg Chemotherapy, Hormonal Therapy Cyclin dependent kinase inhibitor/ aromatase inhibitor CDK 4/6 Yes 2017 In Use
NA Anagrelide Agrylin 1mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Estramustine Phosphate Sodium Emcyt 140 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1981 In Use
NA Cabozantinib Cometriq 20 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Pomalidomide Pomalyst 2 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2013 In Use
NA Ruxolitinib Jakafi 15 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Bromocriptine Mesylate Parlodel Chemotherapy Dopamine Agonist Ergot Derivative Yes 1978 In Use
NA Cabozantinib Cabometyx 20 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Abiraterone acetate Zytiga 250 mg Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Yes 2011 In Use
NA Letrozole Femara 2.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1997 In Use
NA Enasidenib mesylate Idhifa 50 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
NA Pazopanib Votrient 200 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT, Lck, FMS Yes 2009 In Use
NA Lenalidomide Revlimid 5 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2005 In Use
NA Pilocarpine Hydrochloride Pilocarpine 5mg, 10mg Ancillary Therapy Miscellaneous Agent Cholinergic Agent Yes 2020 In Use
NA Lapatinib Tykerb 250 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2007 In Use
NA Crizotinib Xalkori 250 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
NA Erdafitinib Balversa 3mg, 4mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Yes 2019 In Use
NA Encorafenib Braftovi 50mg, 75mg Chemotherapy BRAF Inhibitor V600E Yes 2018 In Use
NA Panobinostat Farydak 10 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use
NA Quizartinib Vanflyta Multiple Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2023 In Use
NA Axitinib Axitinib 5 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Bexarotene Targretin 0.01 Chemotherapy Immunomodulator Retinoic Acid Derivative No 2014 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.